Get started
Author

Kyle Doolan

Observed name: Kyle M. Doolan
ORCID: 0000-0001-8449-4826
Observed ORCID: 0000-0001-8449-4826
OpenAlex ID: A5022558900
Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
2021 · Zhiqiang Ku, Xuping Xie, et al. · Nature Communications · 152
PDF
Conformation-Dependent Epitopes Recognized by Prion Protein Antibodies Probed Using Mutational Scanning and Deep Sequencing
2014 · Kyle M. Doolan, David W. Colby · Journal of Molecular Biology · 49
Author Correction: Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape
2021 · Zhiqiang Ku, Xuping Xie, et al. · Nature Communications · 14
PDF
Identification of the seven critical residues that control ZIKV-DENV cross-reactivity to engineer a non-cross-reactive ZIKV vaccine
2025 · Ariadna Grinyo-Escuer, Srikar Reddy, et al. · Cell Reports · 3
1183 Development of CTIM-76, a highly specific Claudin 6 bispecific antibody
2023 · Joseph Rucker, Ileine Sanchez, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
Abstract 3406: GPRC5D multispecific antibodies with potent anti-tumor activity against multiple myeloma
2025 · Hayley Roth, Daniel Rogers, et al. · Cancer Research · 1
Abstract 1865: Development of CTIM-76, a highly specific Claudin 6 bispecific antibody for treatment of ovarian cancer
2023 · Joseph Rucker, Ileine Sanchez, et al. · Cancer Research · 1
895 Engineering GPRC5D multispecific antibodies: parallel engineering to optimize affinity, developability, and IP
2026 · Trevor Barnes, Hayley Roth, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 5535: GPRC5D multispecific antibodies: Engineering for affinity, cross-species reactivity, and bi/trispecific engagement in multiple myeloma
2026 · Hayley Roth, Trevor Barnes, et al. · Cancer Research
981 GPRC5D multispecific antibodies targeting multiple myeloma
2025 · Daniel Rogers, Hayley Roth, et al. · Journal for ImmunoTherapy of Cancer
PDF
1075 Bispecific and trispecific GPRC5D antibodies with potent cell-killing activity against multiple myeloma
2024 · Hayley Roth, Daniel Rogers, et al. · Journal for ImmunoTherapy of Cancer
Abstract 2374: Bispecific and trispecific GPRC5D antibodies with potent cell-killing activity against multiple myeloma
2024 · Hayley Roth, Daniel Rogers, et al. · Cancer Research
1182 Bispecific GPRC5D antibodies with potent cell-killing activity against multiple myeloma
2023 · Hayley Roth, Ileine Sanchez, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 6305: Bispecific claudin 18.2 and GPRC5D antibodies with potent cell-killing activity for cancer therapeutics
2023 · Ileine Sanchez, Hayley Roth, et al. · Cancer Research
Abstract 1543: Discovery of CCR8 antibodies targeting regulatory T cells to enable tumor sensitization
2023 · Brad Screnci, Hayley Roth, et al. · Cancer Research
Abstract 2892: Development of claudin 6 bispecific antibodies for treatment of ovarian cancer
2022 · Joseph Rucker, Kyle Doolan, et al. · Cancer Research
Works count: 16
Citation count: 222
H-index: 3
I10-index: 3
Year
Topic
Type